Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price target remains the same with $150.00. Don't Miss our ...
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus and ...
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00. Don't Miss our Black Friday Offers: Robert Burns has given ...
Investor's Business Daily on MSN3d
Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHSModerna stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
GlobalData on MSN4d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback